Regenerex Pharma, INC 8-K filings
Current reports — the filing a company makes when something happens that shareholders need to know about before the next quarterly report.
Regenerex Pharma, Inc. has filed a lawsuit against its former Chief Financial Officer, Kenneth W. Perry, alleging fraud, embezzlement, and destruction of financial records.
Regenerex Pharma, Inc. announced the termination of Chief Financial Officer Kenneth Perry for Cause, effective May 2, 2026, following a review of his conduct.
Regenerex Pharma suspends CFO Kenneth Perry pending review of financial oversight and governance concerns, appointing Don E. Ray as interim CFO.
Regenerex Pharma, Inc. announced a change in its fiscal year end from March 31 to December 31, effective September 22, 2025, to align with calendar year reporting.
Regenerex Pharma, Inc. has entered a binding agreement with Holista Colltech Ltd. for exclusive global rights to ovine collagen in advanced wound care.
Regenerex Pharma, Inc. has entered into a strategic licensing agreement with Holista Colltech Ltd. for exclusive rights to high-purity ovine collagen for wound care and U.S. distribution.
Regenerex Pharma announces the appointment of Kenneth W. Perry as Chief Financial Officer, effective March 31, 2025, following the resignation of Brent Wilson due to personal reasons.
Regenerex Pharma has announced the appointment of a new director and CFO, along with the resignation of its previous CFO, Secretary/Treasurer, and board member, all effective December 6th, 2024.